Connor Clark & Lunn Investment Management Ltd. Sells 22,226 Shares of Embecta Corp. (NASDAQ:EMBC)

Connor Clark & Lunn Investment Management Ltd. lowered its position in shares of Embecta Corp. (NASDAQ:EMBC) by 9.9% during the third quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 203,050 shares of the company’s stock after selling 22,226 shares during the period. Connor Clark & Lunn Investment Management Ltd.’s holdings in Embecta were worth $2,863,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors also recently made changes to their positions in EMBC. Copeland Capital Management LLC bought a new stake in shares of Embecta in the third quarter worth $43,000. Iat Reinsurance Co. LTD. bought a new stake in shares of Embecta in the 2nd quarter valued at $50,000. CWM LLC grew its holdings in Embecta by 773.8% in the second quarter. CWM LLC now owns 9,079 shares of the company’s stock worth $113,000 after purchasing an additional 8,040 shares during the period. Canada Pension Plan Investment Board bought a new stake in Embecta in the 2nd quarter valued at about $140,000. Finally, Cardinal Capital Management increased its holdings in shares of Embecta by 16.8% during the second quarter. Cardinal Capital Management now owns 11,753 shares of the company’s stock valued at $147,000 after acquiring an additional 1,691 shares in the last quarter. 93.83% of the stock is currently owned by institutional investors.

Embecta Trading Down 1.3 %

EMBC opened at $13.82 on Monday. Embecta Corp. has a 1-year low of $9.93 and a 1-year high of $19.79. The company has a market cap of $797.44 million, a price-to-earnings ratio of 11.52 and a beta of 0.97. The company’s fifty day moving average price is $14.38 and its two-hundred day moving average price is $14.01.

About Embecta

Embecta Corp., a medical device company, focuses on the provision of various solutions to enhance the health and wellbeing of people living with diabetes. Its products include pen needles, syringes, and safety injection devices, as well as digital applications to assist people with managing patient's diabetes.